MedPage Today (10/16, DePeau-Wilson ) reports, “No individual antipsychotic was associated with better cognitive outcomes than placebo in patients with schizophrenia spectrum disorders (SSD), according to a systematic review and network meta-analysis.” The research “revealed that two first-generation dopamine antagonists” – haloperidol and fluphenazine – “were connected with lower cognitive performance.” The findings were published in JAMA Psychiatry.
Related Links:
— MedPage Today (requires login and subscription)